Editas Medicine to Present at Upcoming June Investor Conferences
Get Alerts EDIT Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., May 24, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it will present company overviews at three upcoming investor conferences in June:
- Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016 at 4:00 p.m. PT (7:00 p.m. ET) in Rancho Palos Verdes, Calif.
- Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 4:30 p.m. ET in New York City
- JMP Securities 2016 Life Sciences Conference on Tuesday, June 21, 2016 at 11:00 a.m. ET in New York City
A live webcast of each presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation. About Editas MedicineEditas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Jesse Baumgartner Stern Investor Relations, Inc. (212) 362-1200 [email protected]Source: Editas Medicine
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
- Creative Capital Announces Appointment of Sam Keisner as Partner
- Tiny Blue Dot Foundation Awards $9M For 11 New Research Grants Exploring the Science of the Perception Box
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Goldman Sachs, Jefferies & Co, JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share